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 ABSTRACT  
α-Dystroglycanopathies are a group of muscular dystrophies characterized by α-DG 
hypoglycosylation and reduced extracellular ligand-binding affinity. Among other genes involved in 
the α-DG glycosylation process, fukutin related protein (FKRP) gene mutations generate a wide range 
of pathologies from mild limb girdle muscular dystrophy 2I (LGMD2I), severe congenital muscular 
dystrophy 1C (MDC1C), to Walker-Warburg Syndrome and Muscle-Eye-Brain disease. FKRP gene 
encodes for a glycosyltransferase that in vivo transfers a ribitol phosphate group from a CDP –ribitol 
present in muscles to α-DG, while in vitro it can be secreted as monomer of 60kDa. Consistently, new 
evidences reported glycosyltransferases in the blood, freely circulating or wrapped within vesicles. 
Although the physiological function of blood stream glycosyltransferases remains unclear, they are 
likely released from blood borne or distant cells. Thus, we hypothesized that freely or wrapped FKRP 
might circulate as an extracellular glycosyltransferase, able to exert a “glycan remodelling” process, 
even at distal compartments. Interestingly, we firstly demonstrated a successful transduction of 
MDC1C blood-derived CD133+ cells and FKRP L276I
KI
 mouse derived satellite cells by a lentiviral 
vector expressing the wild-type of human FKRP gene. Moreover, we showed that LV-FKRP cells 
were driven to release exosomes carrying FKRP.  Similarly, we observed the presence of FKRP 
positive exosomes in the plasma of FKRP L276I
KI
 mice intramuscularly injected with engineered 
satellite cells. The distribution of FKRP protein boosted by exosomes determined its restoration 
within muscle tissues, an overall recovery of α-DG glycosylation and improved muscle strength, 
suggesting a systemic supply of FKRP protein acting as glycosyltransferase. 
 
INTRODUCTION  
The congenital muscular dystrophies (CMDs) are a group of clinically heterogeneous infantile 
autosomal disorders, typically characterized by dystrophic symptoms such as skeletal muscle 
weakness and contractures, marked psychomotor developmental delays, and cardiac and neurological 
defects. In addition to the well-known CMDs dependent on dystrophin mutations (1), α-
Dystroglycanopathy is a newly emerging subgroup determined by gene mutations associated to a 
defective α-Dystroglycan (α-DG) glycosylation. The glycoprotein α-DG is placed on the peripheral 
membrane of muscle tissues, and it is characterized by a peculiar O-mannose –linked glycan structure 
that exerts a key role in binding the internal actin cytoskeleton of muscle fibers to the protein ligands 
of the extracellular matrix basal lamina (i.e. laminin, agrin, and perlecan). Therefore, defects in α-DG 
glycosylation lead to impaired cell membrane integrity, loss of structural stability, fiber damage and 
continuous regeneration/degeneration cycles. The proper α-DG- extracellular matrix (ECM) ligand 
binding function is strictly regulated by the unique structure and the complex glycosylation of all the 
sugar moieties composing the α-DG (2), thus suggesting the existence of several autosomal recessive 
mutations in genes directly involved into glycosylation modifications. Among the most known 
mutated genes, Protein-O-mannosyl transferase 1 (POMT1) and Protein-O-mannosyl transferase 2 
(POMT2), catalyse the initial O-mannosylation of α-DG (3); LARGE acts as a bifunctional 
glycosyltransferase of xylose and glucuronic acid (4). Fukutin-related protein (FKRP) is implicated in 
post-phosphoryl modification of α-DG (5) and underlies both the severe congenital muscular 
dystrophy type 1 (MDC1C) and the mild limb girdle muscular dystrophy type 2I (LGMD2I), two 
forms of dystrophy associated with a wide spectrum of clinical severity (6). In particular, it has been 
recently published that FKRP acts in tandem with Fukutin as transferase of ribitol 5-phosphate 
(Rbo5P), transferring a ribitol phosphate group from CDP-ribitol, a rare sugar unit presented in 
muscle to α-DG (7). Although CDP-ribitol clearly represents a donor substrate for FKRP, the precise 
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sequence of action leading to CDP-ribitol transportation to the Golgi, as well as the exact site where 
ribitol phosphate groups are incorporated into O-mannose glycan structure, is still poorly described 
(8). Moreover, the relegation of glycosyltransferases within ER-Golgi apparatus belongs to a 
glycosylation concept that has been recently out-dated, thanks to the identification of blood derived 
circulating glycosyltransferases that can effect glycans on distant cells and extracellular environment 
(9). In this new scenario, we hypothesized that FKRP might circulate as an extracellular 
glycosyltransferase, able to modify distal glycan structures. Interestingly, we employed a lentiviral 
vector expressing the wild-type of human FKRP gene to demonstrated the feasibility of transducing 
both dystrophic blood derived CD133+ cells, isolated from a MDC1C patient with FKRP gene 
alterations, and satellite cells derived from FKRP L276I
KI
 mouse model (10). Moreover, we showed 
that FKRP transduced cells were driven to release exosomes carrying FKRP.  Similarly, we observed 
the presence of blood freely circulating FKRP carried by exosomes isolated from plasma of FKRP 
L276IKI mice intramuscularly injected with ex vivo-engineered satellite cells. Furthermore, we 
performed exosome tracking in vitro exploiting a microfluidic bioreactor to reproduce in vivo 
kinetics, timing of distribution and fusion to targeted tissues. The dual distribution of FKRP protein 
determined its expression restoration within muscle tissues, an overall recovery of α-DG 
glycosylation, and improved muscle strength, suggesting a systemic supply of FKRP protein acting as 
glycosyltransferase.  
 
RESULTS  
FKRP expression in transduced human MDC1C CD133+ blood-derived stem cells and murine 
FKRP L276I
KI
 satellite cells 
Human MDC1C CD133+ blood-derived stem cells 
Following cells isolation through magnetic columns, CD133+ cells were immediately cultured in 
vitro; culture maintenance did not affect morphology of cells that remained round in shape and 
uniform in size immediately after the isolation (Fig. 1A), as well as after 2 weeks in culture (Fig. 1B). 
98% of magnetically isolated CD133+ stem cells from MDC1C peripheral blood (Fig. 1C, gate) 
(median purity 92,3%)(Fig. 1C’) showed CD45 co-expression (Fig. 1C’’), and the expression of 
CD34 marker (90,1% positivity) (Fig. 1C’’’). Immediately after cells isolation, cells were transduced 
with a lentiviral vector carrying the wild type form of FKRP gene (pLenti-CAG (hFKRP)-Rsv (GFP-
Puro)), with three different MOI: 5, 10 and 20. FACS analyses of GFP expression performed on 
CD133+ blood-derived cells infected with LV-FKRP revealed a transduction efficiency proportional 
to the MOI increase: 48%, 74,8%, and up to 95,2% respectively for MOI of 5, 10 and 20 (Fig. 1D, D’, 
D’’). These data were summarized in the histogram graph in Fig. 1D’’’. Since MOI of 20 presented 
the best outcomes in terms of transduction efficacy (Fig. 1D’’, D’’’), we proceeded to infect MDC1C 
blood-derived CD133+ stem cells with lentiviral MOI 20. Trypan blue exclusion assay performed on 
LV-FKRP CD133+ stem cells infected with this MOI did not display detrimental effects on cell 
proliferation, for all the experimental time points. MOI 20 transduced FKRP CD133+ stem cell 
proliferation curve resembled the characteristic curve of not infected CD133+ blood-derived stem 
cells, with an initial decrease of cell viability and a peak between 15 and 20 days (Fig. 1E). WB 
analysis performed 7 days after infection confirmed the restoration of lentivirus mediated wild type 
fukutin related protein expression in the engineered human MDC1C blood-derived CD133+ stem 
cells (Fig. 1F, lane MOI 20 INF CD133+ MDC1C). Consistently with the specificity of FKRP-STEM 
antibody for the wild type isoform of FKRP, not infected dystrophic CD133+ blood-derived stem 
cells (Fig. 1F, lane CD133+ MDC1C) expressing mutated protein did not show any positive 
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corresponding band at 60kDa, while expression of FKRP in human healthy CD133+ blood derived 
stem cells was clearly detectable (Fig. 1F, lane CD133 CTR+). 
FKRP L276I
KI
 satellite cells 
Satellite cells population was isolated from FKRP L276IKI new born mice and plated in 48-wells 
tissue culture plates in expansion medium. FACS analysis demonstrated that 97,6% of isolated cells 
were Pax7+ (Fig. 2A) and 80.3% of Pax7+ cells co-expressed CD29 marker (Fig. 2A’). SCs 
morphology and expression of specific myogenic markers were evaluated at different time-points 
after culturing cells in myogenic differentiation medium (Fig. 2E, F, and G; Supplementary Fig. S1). 
Before the supplementation of serum starvation medium (T0), SCs showed the maintenance of Pax7 
(in red in Fig. 2E) and desmin (in green in Fig. 2E) expression, while at T7 they started to elongate 
and form small Pax7-desmin+ myotubes (Fig. 2F) that increased in number and size after 14 days 
(T14) (Fig. 2G). We determined which pLenti-CAG (hFKRP)-Rsv (GFP-Puro) MOI was most 
effective in transducing FKRP L276IKI SCs in terms of SC viability and transduction efficiency. 
FKRP L276IKI SCs infected with lentiviral MOI of 10 and 20 did not show negative effects on 
viability compared to the not infected cells for all the time points, as confirmed by Trypan Blue 
Exclusion assay (Fig. 2H). Likewise, transduction with higher MOI (MOI 40) generated a tendency 
towards a slower proliferation rate of FKRP L276IKI SCs (determined by about 5% of cell mortality) 
(Fig. 2H). Interestingly, proliferation rate of FKRP L276IKI SCs infected with LV empty (pLenti-Rsv 
(GFP-Puro)) did not display any statistical differences between MOI 10, 20 and 40 (Fig. 2I). For MOI 
40 it is only noticeable that cell proliferation seemed to face a not significant tendency towards a 
proliferation rate slow down starting from day 15 that might be caused by the occurrence of 3,5% cell 
mortality. Thus, we can exclude the occurrence of FKRP L276I
KI
 SCs toxicity induced by lentivirus 
vectors, either the one carrying wild type FKRP isoform or the empty GFP cassette, even for long 
time of culture (25 days). SCs fusion index expressed as % of myotubes nuclei/ number of total nuclei 
was found to be comparable between cells infected with MOI 10, 20 and 40 (Fig. 2L). We evaluated 
also the fusion index of FKRP L276IKI SCs infected with LV empty (pLenti-Rsv (GFP-Puro))(data 
not shown), but no differences were evidenced between MOI 10, 20 and 40, which maintained values 
comparable to not-infected FKRP L276IKI SCs (
˷
30% myotubes nuclei/total nuclei)(Fig. 2L). A not 
statistically different fusion index was evaluated for MOI 40 infected FKRP L276IKI SCs that might 
be reasonably caused by an overall slightly decreased cell number rather than by a decreased 
differentiation capacity. GFP expression performed on transduced FKRP L276IKI SCs infected with 
LV-FKRP revealed a transduction efficiency after 72 h proportional to the MOI increase: 41,3%, 
89,2% and 89,8% respectively for MOI of 10, 20 and 40. The GFP expression grew up to 99.2% after 
puromycin selection in all MOI tested. FKRP evaluation by WB analysis highlighted an increasing 
trend of protein expression between MOI of 10 and 20, while the MOI of 40 seemed to represent a 
steady point leading to FKRP expression plateau (Fig. 2M). Of note the achievement of FKRP 
expression plateau at MOI 40 is still associated to a constant level of α-DG glycosylation that seemed 
not to present MOI-dependent changes (Fig. 2M). IF staining of MOI 20 LV- FKRP L276IKI SCs by 
anti- GFP and anti FKRP-STEM antibodies confirmed the diffusion of GFP (in green in Fig. 2N; 
Supplementary Fig. S1D’) within the cell cytoplasm, while exogenous FKRP (in red in Fig. 2N; 
Supplementary Fig. S1D’’) was also found cytoplasmic but more localized nearby the cell nucleus. 
According to these results, for the in vivo experiments we infected FKRP L276I
KI 
SCs with the 
optimal MOI 20 giving the higher transduction efficiency and the lower cell mortality. 
In vitro release of wild type FKRP carrying- exosome 
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In line with previous results showing in vitro secretion on FKRP (11), we have hypothesized that 
FKRP protein could be transported by exosomes released in vitro from transduced cells. For this 
purpose, we have isolated exosomes from MOI 20 transduced MDC1C CD133+ blood-derived stem 
cell and MOI 20 transduced FKRP L276IKI SCs supernatants by size exclusion chromatography 
(SEC) procedure. NTA analysis confirmed the presence of exosomes in both cell populations. 
MDC1C CD133+ blood-derived stem cells released exosomes (NTA concentration 1,17x10
9  
particles/ml) with a mean size of 154,1 nm and a mode size of 128,2 nm (Fig. 3A), while FKRP 
L276
KI
 SCs-derived exosomes  (NTA concentration 1,79x10
9 
particles/ml), showed a mean size of 
166,8 nm and a mode size of 139,9 nm (Fig. 3B). FACS analysis confirmed the expression of CD63 
and CD81 tetraspanins both in MDC1C CD133+ derived exosomes (92,2% positivity for CD63 
marker, 82,5% positivity for CD81 marker) (Fig. 3C) and in FKRP L276I
KI
 SCs-secreted particles 
(88% positivity for CD63 marker, 89% positivity for CD81 marker)(Fig. 3D). Both exosome 
preparations exhibited a cup-shaped morphology in transmission electron microscopic images (Fig. 
3E, F; Supplementary Fig. S2A, S2B). Overall, exosome dimensions and morphology were found to 
be comparable between the two observed populations (92,7 nm ± 39,5 nm SD for MDC1C CD133+ 
blood-derived stem cells exosomes, and 109 nm ± 46,3 nm SD for FKRP L276I
KI
 SCs secreted 
exosomes). WB was performed using anti FKRP-STEM antibody on transduced cell lysates (Fig 3G, 
MOI 20 INF CD133+ MDC1C cells, lane 1; MOI 20 INF L276IKI FKRP SCs, lane 3) and the related 
exosomes (Fig. 3G, MOI 20 INF CD133+ MDC1C EXOs, MOI 20 INF L276I
KI
 FKRP SCs, lanes 2, 
4). The biochemical analysis showed exogenous FKRP corresponding band at 60 kDa, in the infected 
CD133+ cell and SCs lysates and in the corresponding secreted exosome lanes. The absence of Ago2 
protein staining (90KDa) let exclude any kind of contamination during exosome samples preparation 
(12); TSG-101 detection proved the specificity of exosomal FKRP expression (Fig. 3G) (13).  
In vivo transplantation of LV-FKRP L276I
KI
 satellite cells into FKRP L276I
KI 
mouse models. 
Satellite cells isolated from FKRP L276I
KI
 new born mice and engineered with the lentiviral vector 
expressing the full length wild-type isoform of FKRP gene were intramuscularly transplanted into the 
right tibialis anterior of 12 months-old FKRP L276I
KI 
mice. We aimed at demonstrating that 1) 
infected LV-FKRP L276I
KI 
SCs could fuse with the host muscle tissue surrounding the transplantation 
site, thus ameliorating the dystrophic phenotype, while 2) the release of exosomes carrying wild type 
FKRP was able to induce an overall expression of FKRP and α-DG glycosylation, even at distant 
compartments. Firstly, we wanted to detect whether transduced cell engraftment contributes to wild 
type FKRP expression and consequently to α-DG glycosylation in a cell number- dependent manner. 
WBs confirmed wild type exogenous FKRP expression in the right TAs of transplanted mice for all 
the conditions, highlighting an increasing trend of protein expression as result of the different cell 
numbers injected (Fig. 4A, B, C). Mice injected with 35x10
3
 showed weak bands (Fig. 4A), while 
transplantation of 75x10
3
 cells (Fig. 4B) determined an increased strong signal that faced a steady 
point leading to FKRP expression plateau at 100x10
3
 injected cells (Fig. 4C). The FKRP antibody 
detected a faint band of exogenous FKRP at approximately 60 KDa even in the contralateral TAs thus 
providing the first evidence of a systemic FKRP distribution as exosome cargo (Fig. 4). FKRP 
biochemical detection in TAs from not injected mice (Fig. 4) and C57Bl mouse (Fig. 4) confirmed the 
specificity of the wild type FKRP detection in the contralateral TAs. Since the FKRP-STEM antibody 
was not able to detect endogenous mutated FKRP (10, 14), no bands were observed in the NI TAs 
(Fig. 4A), while the not mutated form of C57Bl mouse was clearly detectable. Injected TAs muscles 
were also biochemically analysed for the recovery of α-DG glycosylation. The lowest dose of 
engineered-satellite cells injection didn’t elicit a significant difference in α-DG glycosylation as 
compared to untreated muscles (Fig. 4D). On the contrary, 75x103 and 100x103 cells injected mice 
TAs showed a slight improvement in α-dystroglycan glycosylation, as observed by the increasing of 
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the signal smear, thus confirming a massive restoration of FKRP function (Fig. 4D, E). IF staining of 
TA sections showed muscle fiber expression of FKRP in a cell dose-dependent fashion. The 35x103 
cell injected mice still display a patchy sarcolemmal expression of FKRP whereas higher cell dose, in 
particular the condition at 75 x10
3 
cells, prompted a more uniform and widespread sarcolemmal 
fluorescence signal (Fig. 5B, C and D). TAs from animal injected with 100x10
3
 displayed exogenous 
FKRP expression comparable to the 75x10
3
 transplanted mice (Fig. 5D), whereas 35x10
3
 injection 
was not sufficient to induce an overall FKRP rescue, rather confined in few myofibers (Fig. 5B). Not 
injected mice did not show any positive staining (Fig. 5A). Exogenous FKRP perinuclear staining was 
also found in some muscle fibers (white arrows in Fig. 5C, and D inserts). Cell dose-dependent GFP 
expression (in green in Fig. 5) at cytoplasmic level was found with a marked positive staining in TAs 
injected with 75 and 100x103 cells (Fig. 5). Moreover we observed FKRP sarcolemma expression in 
both GFP+ and GFP- treated muscle fibers (Fig. 5). The staining against the glycosylated epitopes of 
α-DG showed patchy staining of glycosylated α-DG in the sarcolemma of not injected FKRP L276IKI 
skeletal muscles, confirming the occurrence of α-DG hypoglycosylation in FKRP L276IKI mice (Fig. 
5A’’). Conversely, treated muscles displayed a stronger positive signal as the number of injected cells 
increased (Fig. 5B’’, C’’, D’’). The FKRP L276IKI mutant mice exhibit a mild phenotype of muscular 
dystrophy represented as myofiber regeneration/degeneration, fiber size variability and fibrosis in the 
later stages of disease progression. Examination of the muscle morphology by H&E staining indicates 
similar pathological phenotypes between TA skeletal muscles of the untreated and treated FKRP 
L276I
KI
, as demonstrated by the presence of areas of necrotic fibers and a number of centrally 
nucleated fibers (Supplementary Fig. S3).  
Exosomes-mediated systemic distribution of FKRP protein 
In order to demonstrate the systemic trafficking of exosomes carrying FKRP prompted by the 
injection of transduced FKRP L276I
KI
 SCs, plasma was collected from all the FKRP L276I
KI
 injected 
mice, as well as from the not injected ones, for exosome isolation by SEC procedure. Unprocessed 
plasma and SEC elution plasma fractions were harvested and biochemically analysed. WB showed 
60kDa FKRP corresponding bands for unprocessed plasma and plasma isolated exosomes from all the 
FKRP L276IKI injected mice (Supplementary Fig. S4). No signal was detected in exosome-depleted 
plasma, suggesting the prime role exerted by exosomes in determining exogenous FKRP protein 
blood circulation (Supplementary Fig. S4). Further WB characterizations of exosomes isolated from 
plasma of FKRP L276IKI injected mice and not injected mice have been performed and showed the 
presence of the exogenous FKRP glycosyltransferase as exosome cargo in a cell number- dependent 
fashion (Fig. 6A). As expected, FKRP was not detected within the plasma exosomes isolated from the 
not injected animals (Fig. 6A). The presence of a clear TSG-101 staining confirmed the exosomal 
origin of all samples (Fig. 6A). Plasma exosomes were also characterized by TEM and NTA analysis. 
TEM image exhibited the presence of cup-shaped particles, in the range of typical exosome 
dimensions (mean value 90 nm ± 36,6 nm SD) (Fig. 6B; Supplementary Fig. S2C). Nanosight graph 
underlines a concentration of 1,13x10
9
 particles/ml, a mean size of 142.2 nm and a mode size of 130.8 
nm (Fig. 6C). 
The systemic effect of engineered-cells intramuscular transplantation was also evaluated by 
measuring the exogenous FKRP expression and α-DG glycosylation in the hearts of injected muscles. 
Heart muscles displayed a stronger positive signal as the number of injected cells increased from 
35x10
3
 to 75x10
3
, reaching a plateau between 75x10
3
 and 100x10
3
 injected mice. Similarly to WBs 
performed for TAs, the specificity of the FKRP band as wild type protein expression elicited by an 
exosomal source is ensured by the lack of detectable signal in the NI mouse hearts, while the positive 
control from C57Bl mouse heart showed a clear band corresponding to FKRP protein. As regards α-
7 
DG glycosylation, no pronounced differences were found among the three groups of injection, but an 
increased glycosylation was still observed taking in account the not injected mice and the positive 
control from C57Bl mouse (Fig. 6D, E).  
In vitro modelling of dynamic FKRP carrying-exosome trafficking 
In order to study the in vivo exosome trafficking dynamic, we reproduced an in vitro model 
mimicking the blood circulating FKRP shielded and transported within exosomes. Figure 7A shows 
the in vitro trafficking model of exosomes carrying wild type FKRP, output from infected FKRP 
L276IKI SCs and moving towards target cells within a miniaturized microfluidic bioreactor.  GFP 
expression detected by confocal fluorescent microscopy confirmed the efficient infection of 1x106 
FKRP L276IKI SCs by lentiviral MOI of 20 (Fig. 7B). Infected FKRP L276IKI SCs were also labelled 
with PKH26 red membrane marker before being seeded into scaffold, determining the diffused signals 
of GFP and PKH26 within the cell cytoplasm (Fig. 7C; Supplementary Fig. S5A’’). PKH26+ infected 
FKRP L276I
KI
 SCs were able to continuously release PKH26+ exosomes (Fig. 7D) that were tracked 
for 8 hours within the microfluidic channels by confocal fluorescent microscopy at 100X 
magnification (Fig. 7D). Once exosomes from infected FKRP L276I
KI
 SCs reached the not infected 
SCs seeded into the scaffold hosted in the second chamber, they were able to fuse randomly with 
target cells, conveying the wild type FKRP as cargo protein and favouring its expression. IF analysis 
performed after 8 hours on the not infected FKRP L276I
KI
 SCs, which had been in contact with FKRP 
carrying- exosomes released from transduced cells, highlighted an exogenous cytoplasmic FKRP 
positive signal (in green in Fig. 7E and F), mainly confined to cells that internalized exosomes (in red 
in Fig. 7E and F; Supplementary Fig. S5B’’). 
Muscle function analysis 
FKRP L276I
KI
 mice intramuscularly transplanted with engineered satellite cells were 
evaluated by two functional tests, treadmill and rotarod, which are commonly used to determine 
mice endurance. Treadmill results showed that mice that did not receive cell transplant found 
extremely difficult to accomplish the test until the end of the experimental time points. In general, 
FKRP L276IKI mice seemed to become familiar with the treadmill after an initial training session (-
T7) and are willing to run for the first week (T7), even though they maintained the running distance 
constantly below 400 meters and the running time around 1000 seconds. At T14, these mice became 
unable to sustain downhill treadmill running and showed extreme fatigue, implying an increased 
sensitivity to exercise-induced fatigue. Conversely, FKRP L276I
KI
 transplanted mice displayed a 
functional behaviour determined by the number of injected LV-FKRP satellite cells and consistent 
with the FKRP re-expression and α-DG glycosylation level. Overall, FKRP L276I
KI
 treated mice 
showed a significant increase in distance traveled compared both to the running distance measured 
before the injections and to FKRP L276IKI untreated animals. Interestingly, FKRP L276IKI mice 
injected with 75 and 100K cells had a fast positive response to exercise-induced fatigue, both 
showing an improvement trend starting immediately after the injection of LV- FKRP L276IKI SCs, 
even though the condition of 75K displayed a more marked and noticeable enhancement.  75 x10
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seemed to be the condition determining a real and long lasting increase of the running distance and 
time, with a leap from 403 meters (averaged running distance) at T0 to 698,7 meters at T7, and up to 
724 meters a T14. Interestingly, the trend of the 75x10
3
 transplanted animal running time underwent 
a fast increase in the first 7 days post injection (T0 averaged running time 779,2 seconds vs. T7 
average running time 2827 seconds), which settled at T14 around 2411 seconds. 100x103 
transplanted mouse outcomes from the treadmill test showed a slower increase trend that reached the 
maximum running distance and time at T7, displaying the best performance, followed by plateau 
level (at T14, averaged running distance: 547 meters; averaged running time: 1898 seconds) (Fig. 
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8A, B). FKRP L276IKI mice treated with 35K cells showed instead a higher level of interindividual 
variability with a slow decrease of the performance. More in details, despite a tendency towards a 
slight increase of the running distance and time within 7 days after injection, at T14 the 35x10
3
 
transplanted mice regressed to functional performances similar to the pre-injection  (averaged 
running distance: 301 meters; averaged running time: 1315 seconds). The averaged coefficient of 
variations at 14 days after treatment, calculated considering the baseline level before the cell 
injection, was -86% for untreated FKRP L276IKI mice, -18% for FKRP L276IKI treated with 35K 
cells, and respectively +95% and +62% for FKRP L276I
KI
 treated with 75K and 100K infected 
FKRP L276IKI SCs. With the rotarod test muscle strength, coordination, balance, and condition of 
FKRP L276IKI mice can be determined. Rotarod functional measures confirmed the poor 
performances of not injected mice, as well as the cell number-dependent functional improvements of 
the transplanted FKRP L276IKI mice. On the rotarod, untreated FKRP L276IKI mice hardly ever run 
for the 300 seconds. Running performance of not injected FKRP L276I
KI
 mice remains comparable 
for two weeks and started to decrease significantly within T7 and T14. 35x10
3
 transplanted mice 
showed a marked increase in the first week after the treatment after which the running time was 
maintained almost constant throughout the experimental points (T14 averaged running time: 377 
seconds). Similarly, 75 and 100x10
3
 transplanted mice showed an increase in running seconds 
during the first week after the injection (T7 averaged running time: 418 seconds and 398 seconds, 
respectively)(Fig. 8C). In both cases, even though there were further improvements of the 
performance at T14 (75 x103 transplanted mice, averaged running time: 429 seconds; 100x103 
transplanted mice, averaged running time: 411 seconds) the increase trend remarkably slowed down 
reaching plateau levels. For both functional measurements, the injected and not injected FKRP 
L276IKI mouse performances were compared to the outcomes from C57Bl mice (n=5; treadmill 
averaged running distance and time: 710 meters and 2788 seconds; rotarod averaged running time: 
437 seconds). Only the 75x10
3 
injected mice showed an improvement trend ending up in 
performance comparable to the C57Bl mice at T7 and T14 (Fig. 8A, B, C).  
DISCUSSION  
α-DG is a glycoprotein sited on muscle peripheral membranes (15, 16), that undergoes 
glycosyltransferase-mediated N-glycosylation, mucin-type O-glycosylation, O-mannosylation, and an 
identified phosphorylated O-mannosyl glycan. While loss of N-linked glycosylation on α-DG has no 
effects on its ability to bind extracellular ligands, defects in O-linked glycosylation result in α-DG 
hypoglycosylation and defective binding with laminin, neurexin, and agrin (17), giving rise to 
congenital disorders named dystroglycanopathies. These latter features can also distinguish a family 
of muscular dystrophies with a wild clinical phenotype spectrum, ranging from congenital muscular 
dystrophy (CMD) with brain and eye involvement in severe cases, to limb-girdle muscular dystrophy 
(LGMD) in milder instances. Mutations in FKRP gene encoding the glycosyltransferase fukutin-
related protein determine the occurrence of untreatable limb-girdle muscular dystrophy 2I and 
MDC1C. The FKRP L276I
KI
 model mimicked the LGMD2I pathology in nearly all aspects, including 
the major histopathology as well as the biochemical deficiencies (10). Even though no therapeutic 
efforts have been completely satisfactory, recent encouraging results came out from the 
overexpression of the glycosyltransferase LARGE (14), and the use of adeno-associated Virus 9 
(AVV9)-FKRP that allows the systemic expression of fukutin related protein (10). In line with these 
findings, we firstly isolated and infected MDC1C CD133+ blood-derived stem cells with lentiviral 
vector carrying the wild type form of human FKRP gene. FKRP-STEM antibody was used to 
specifically recognize the exogenous wild type FKRP from the endogenous mutated one (10). This 
way, we demonstrated the restoration of exogenous isoform of FKRP protein expression in vitro. The 
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lively interest in the novel role of FKRP as glycosyltransferase and the emerging idea of circulating 
glycosyltransferases (9) has brought out the hypothesis of a cell-mediated release of FKRP in vitro 
and in vivo (11). In agreement with this expectation, it has been shown that fukutin, another 
glycosyltransferase responsible for Fukuyama muscular dystrophy, is secreted into culture media (18). 
Furthermore, considering that the main route for glycosyltransferases to be transported to Golgi is 
protected and packaged into vesicles, we considered the involvement of exosomes as vesicles carrying 
FKRP. Exosomes are a homogeneous population of extracellular vesicles attracting particular 
attention for their ability to deliver cargos to cells in remote locations. In addition to genetic materials 
(19) and  proteins, exosomes can be  also enriched in post-translational modifier proteins, such as 
kinases, phosphatases, and glycosyltransferases, suggesting that FKRP can be effectively carried by 
exosomes released from transduced cells (20). Interestingly, WB analyses confirmed that the infection 
of MDC1C CD133+ stem cells and FKRP L267IKI SCs prompted the release of exosomes conveying 
the wild type form of FKRP. These results reasonably supported the hypothesis that in vivo exosomes 
can equally traffic and maintain the ability to deliver the glycosyltransferase to receiving cells. To 
demonstrate the in vivo role of exosomes carrying the FKRP protein and in order to present the 
potential clinical application of LV-FKRP cell therapy, we performed in vivo experiments in the 
FKRP L267I
KI
 mouse model of the LGMD2I (3). We carried out an autologous transplantation by 
intramuscularly injecting three different doses of LV-FKRP satellite cells into the TA muscles of 
FKRP L267I
KI
 recipients. The need for an autologous transplantation was due to the absence of an 
immunodeficient FKRP L267I
KI 
animal model. The successful rescue of the exogenous and functional 
FKRP protein expression and the restoration of the α-dystroglycan glycosylation were demonstrated 
both by WB and IF analyses. FKRP, as well α-DG showed a cell-dose dependent response in the 
injected FKRP L267I
KI
 TAs: 35x10
3
 LV-FKRP SCs was sufficient to determine a weak FKRP 
recovery in the injected TAs, but it was inadequate to prompt a clear increase of glycosylation; 75x 
103 and 100x 103 SC injection induced both marked FKRP signals and enlarged α-DG smears, 
corresponding to enhanced glycosylation levels. Indeed, it seems that there is a functional window for 
an effective recovery of FKRP expression and the consequent α-DG glycosylation: 35x103 SCs 
represented a dose below the bare minimum, while 100x 103 SCs was a plateau dose beyond that an 
additional contribution of LV-FKRP cells did not further improve the FKRP and α-DG expression.  
Interestingly, unless previous studies localized FKRP expression in resident Golgi and endoplasmic 
reticulum, as punctuate dots in the cytoplasmic compartments of myofibers (3), we have detected 
FKRP positive signal at the sarcolemma level. This result is in line with previous studies showing a 
co-localization with α-DG (21) and suggesting that FKRP activity is required at sarcolemma for 
normal muscle function. Moreover we observed two different type of staining: the first consisting in 
FKRP+ sarcolemma of cytoplasm GFP negative muscle fibers; the second seeing cytoplasm GFP+ 
fibers, together with the presence of perinuclear FKRP+ cells. These results would imply two 
different mechanisms of FKRP expression, one mediated by satellite cell fusion, and the other by 
exosome release. The staining against the glycosylated epitopes of α-DG showed a stronger positive 
sarcolemma signal in treated animals as the number of injected cells increased. These observations 
confirmed that the level of functionally glycosylated α-DG in the injected FKRP L276IKI mice is 
linked to FKRP expression. Additionally, we demonstrated that not only engineered FKRP L276IKI 
SCs secreted in vitro FKRP-positive exosomes expressing TSG-101 marker, but also we found 
FKRP-exosomes circulating in the plasma of transplanted FKRP L276IKI mice. Of note, exosome-
depleted plasma of FKRP L267IKI SCs injected mice did not show the expression of FKRP, further 
suggesting that blood circulation of exogenous FKRP protein is determined by exosomes systemic 
trafficking. The presence of FKRP-exosomes promoted systemic FKRP expression and improved 
muscle recovery of FKRP L276I
KI 
transplanted mice. In particular, exosome boosted systemic FKRP 
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expression enhances FKRP expression and α-DG glycosylation in hearts of intramuscularly 
transplanted FKRP L276IKI mice. Since heart is one of the most compromised compartments in the 
FKRP L276IKI animal model (10), implicating a low endurance and performances for exercises, the 
results obtained from treadmill and rotarod assessments can be interpreted as a general amelioration 
of cardiac functionality, aerobic capacity and motor recovery. Although treated FKRP L276I
KI
 mice 
resulted in increased rotarod performance and resistance to eccentric contractions, histopathology was 
not different from untreated FKRP L276I
KI
 mice. It is likely that LV-FKRP SCs may continually 
deliver FKRP positive exosomes to the mouse hearts, exerting a cardioprotective role. The cellular 
and molecular mechanisms of exosome membrane fusion to the plasma membrane of specific target 
cells are still undetermined, even though the aspects of their interactions are starting to emerge. Once 
released, exosomes can slide on target cell surfaces, reduce their movements and finally bind in an 
adhesion molecules dependent manner (i.e. integrin) (22). Interestingly, it has been demonstrated that 
fractions of exosomes undergo a cell uptake via different form of endocytosis for releasing their cargo 
into the cytoplasm, while other exosomes may associate and fuse with plasma membrane. This 
process determines the ensuing insertion of exosome membrane in the target cell plasma membrane, 
where either they dock or eventually discharge to the cytosol their luminal cargo molecules. From our 
point of view, FKRP immunofluorescence staining of injected FKRP L276I
KI
 muscle likely mirrors 
the latter exosomal fusion pathway, as demonstrated by the localization of positive FKRP signal 
around muscle membranes. Therefore, it is reasonable to think that exosome carrying FKRP, upon 
sliding and fusion with muscle fiber, would remain stuck at the sarcolemma level maybe due to the 
specificity of FKRP function in muscle tissue. There are also fractions of exosomes that, once 
released in the extracellular space, continue to travel through extracellular fluid to reach biological 
fluids (i.e. blood), and then towards body sited located far from their cell origin (23). To investigate 
the cell- to cell transmission of systemic exosomal FKRP, we took advantage of miniaturized 
microfluidic system allowing for the culture of two cell populations in two separate but connected 
chambers. The presence of an optical transparent tubing connecting the chambers guaranteed the 
direct observation of FKRP trafficked by exosomes from LV-FKRP L276IKI SCs on one side 
(exosomal source) to not infected FKRP L276IKI cells on the other side (target cells). The selective 
exosome uptake on only one side was ensured by the application of a unidirectional medium flow, 
simulating a systemic circulation directing exosomal FKRP from the blood to distal compartment. By 
using this miniaturized microfluidic system, we confirmed that FKRP can be continuously and 
directionally transmitted via circulating exosomes towards target cells, where they can fuse and 
induce a fast expression of functional exogenous FKRP protein. The short timing (24 hours) required 
in vitro for exosome-mediated FKRP restoration in FKRP L276I
KI
 SCs are consistent with the rapid 
systemic exosome contributions (15 days) to FKRP expression, α-DG glycosylation and general 
amelioration. However, further investigations would be necessary to better investigate the long-term 
beneficial effects and to unravel mechanisms of in vivo exosomal FKRP spreading and tissue 
selectivity. Together, these data demonstrated that muscular dystrophies associated with α-DG 
glycosylation defects can be treated by a combined gene and cell therapy aimed at restoring FKRP 
expression and function. Exosomes carrying FKRP can also unexpectedly sustain these strategies, 
offering the possibility to achieve systemic and general outcomes and to boost the effect of an 
intramuscular injection. 
MATERIALS AND METHODS 
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Cell cultures 
Isolation and FACS characterization of MDC1C blood-derived CD133+ stem cells 
CD133+ blood-derived stem cells were isolated from a MDC1C patient affected by two heterozygous 
mutations in FKRP gene: c518T>G and c1087G>C, after obtaining related informed consent and 
according to Guidelines by the Committee on the Use of Human Subjects in Research at Policlinico 
Hospital of Milan. Blood sample was processed through a MACS magnetic column (Miltenyi Biotec; 
Bergisch Gladbach, Germany), as previously described (24). CD133+ purity was evaluated by FACS 
analysis. For three-color flow cytometric analysis, at least 1x10
5
 cells from peripheral blood were 
incubated with the following monoclonal antibodies (MoAbs): anti-CD133/2-phycoerythrin (PE) 
Miltenyi Biotec; Bergisch Gladbach, Germany), anti-CD34-Allophycocyanin (APC) and anti-CD45-
FITC (Becton Dickinson, Immunocytometry Systems; San Diego, California, USA). For each MoAb, 
an appropriate isotype-matched mouse immunoglobulin was used as control. After staining, 
performed at 4°C for 20 minutes, cell suspensions were washed in PBS containing 1% heat 
inactivated foetal calf serum (FCS) (Gibco,Thermo Fisher Scientific; Waltham, Massachusetts, USA) 
and 0.1% sodium azide. Cells were analysed using a FC500 cytomics flow cytometer (Beckman 
Coulter; Brea, California, USA) and 2.1 CXP software. Each analysis included at least 15,000–30,000 
events. A light-scatter gate was set up to eliminate cell debris from the analysis. The percentage of 
CD133+ cells present in the sample was assessed after correction for the percentage of cells reactive 
with the isotype control. 
Isolation, FACS characterization and myogenic differentiation of FKRP L276I
KI
 satellite cells  
Satellite cells (SCs) were obtained from FKRP L276I
KI
 new born mice as previously described (25). 
FKRP L276I
KI
 mice were developed by Professor Qilong Lu (McColl-Lockwood Laboratory for 
Muscular Dystrophy Research, Neuromuscular/ALS Center, Carolina Medical Center, Charlotte, 
North Carolina, USA). FKRP L276I
KI
 strain was created by knocking in the human mutation 
(nucleotide C826 to A) into the coding sequence of the mouse FKRP gene, resulting in amino acid 
replacement leucine 276 to isoleucine (L276I). Animals were housed in Charles River Laboratories 
(Calco, Italy) and provided with unlimited supply of drinking water and food. Briefly, hind limb 
muscles were washed in 1X phosphate-buffered saline (PBS: 8g/l NaCl, 0,2g/l KCl, 1,44g/l 
Na2HPO4, 0,24g/l KH2PO4 in distilled water; pH7.4) for blood cleansing. Muscles were placed in 
Dulbecco's modified Eagle's medium (DMEM) (Thermo Fisher Scientific; Waltham, Massachusetts, 
USA) with penicillin/streptomycin (100 µL/10ml) and fungizone (120 µL/10ml) for a manual 
connective and adipose tissue, blood vessel and nerve bundle removal under a dissection microscope. 
Subsequently, muscular tissue was mechanically homogenized and enzymatically digested for 30 min 
at 37 °C with a solution of collagenase V (Sigma-Aldrich; St. Louis, Missouri, USA) 0,11 mg/ml, 
dispase (Gibco; Thermo Fisher Scientific; Waltham, Massachusetts, USA) 0,45 mg/ml, DNase 
(Roche; Basilea, Switzerland) 0,01 mg/ml in 12 ml of Hank’s balance salt solution (HBSS). The 
mixture was filtered with a cell strainer (70µm), and incubated for 15 minutes. Cells were centrifuged 
at 458g for 20 minutes at RT.  Finally, the pellet was suspended in DMEM at 20% of FBS with 
antibiotics, 1% embryonic extract chicken (CEE) (Gibco, Thermo Fisher Scientific; Waltham, 
Massachusetts, USA) and 2% horse serum (HS) (Gibco, Thermo Fisher Scientific; Waltham, 
Massachusetts, USA). Suspended cells were counted by Trypan blue (Sigma-Aldrich; St. Louis, 
Missouri, USA) and plated at a final density of 380 cellule/cm
2
 in collagen-treated dishes at 37 °C, 
5% CO2. Plates were incubated overnight and fresh medium was then replaced. SCs were 
phenotypically characterized by cytofluorimetric analysis, as already described. SCs were incubated 
with Pax7 (Hybridoma Bank; Lowa, USA) and CD29-FITC (Milteni Biotech; Bergisch Gladbach, 
Germany). For the first staining, SCs were fixed with 1,5% paraformaldehyde, followed by an 
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overnight incubation with the primary antibody (dilution 1:10) at 4 C° and by an incubation with 
monoclonal anti-mouse 488 Alexa Fluor secondary antibody (Molecular Probe, Thermo Fisher 
Scientific; Waltham, Massachusetts, USA) (dilution 1:100). CD29 was detected incubating cells at 
4°C for 20 minutes. Anti-7-alpha-actin-mycin D (7-AAD) (Becton Dickinson, Immunocytometry 
Systems; San Diego, California, USA) staining was used to evaluate cells vitality. After staining, 
performed at 4°C for 20 minutes, cell suspensions were washed in PBS containing 1% heat 
inactivated FBS and 0.1% sodium azide. Cells were analysed using a FC500 cytomics flow cytometer 
(Beckman Coulter; Brea, California, USA) and 2.1 CXP software. Each analysis included at least 
15,000–30,000 events. In vitro immunofluorescence staining (IF) was also performed to assess the 
SCs myogenic differentiation. After reaching a confluence of 90%, the growing medium was replaced 
with DMEM 2% HS (differentiation medium), to induce SC myogenic differentiation in serum 
starvation conditions. Briefly, cells were fixed in formaldehyde 4% for 10 minutes at room 
temperature, and then incubated in blocking solution (5% of FBS, 2% of HS, 0,3% TRITON in 
PBS1X) for 30 minutes. SCs were incubated overnight with Pax7 antibody (dilution 1:20) 
(Hybridoma bank; Lowa, USA) at 4°C, followed by a staining with the α-mouse biotinilated (dilution 
1:100) for 30 minutes and with Cy3-streptavidin-conjugated secondary antibody (Sigma-Aldrich; St. 
Louis, Missouri, USA) for 1 hour. Subsequently, SCs were incubated with desmin antibody (diluted 
1:50) (Abcam; Cambridge, UK) for 1 hour and developed with anti-rabbit Alexa Fluor 488 antibody 
(Molecular Probe, Thermo Fisher Scientific; Waltham, Massachusetts, USA) (diluted 1:100). Nuclei 
were stained with DAPI (4′,6-Diamidino-2-phenylindole dihydrochloride, Sigma-Aldrich; St. Louis, 
Missouri, USA). SCs were analysed by IF at three different time points: T0, before inducing 
myogenic differentiation, T7 and T14, respectively 7 and 14 days in differentiation conditions. Images 
were captured with Leica TCS SP2 confocal microscope. 
Transduction of MDC1C CD133+ blood-derived stem cells and FKRP L276I
KI
 satellite cells  
Lentiviral vector design  
The lentiviral vector was produced by AMS Biotechnology Company (AMSBIO; Abingdon, UK) as 
previously described (26). The target gene (human FKRP: NM_001039885.2) was obtained from a 
gene bank and it was sub-cloned into expression lentivector via Eco cloning technology (non-enzyme 
based cloning technique). The target gene was expressed under the CMV early enhancer/chicken b-
actin [CAG] promoter. GFP-Puromycin reporter gene was expressed under a Rous sarcoma virus 
[Rsv] promoter. Thus, the target and reporter genes were independently expressed by two different 
promoters. Infected cells were selected using Puromycin linked to GFP. No tag was added to the 
expressed gene. Empty lentiviral vector with only Rsv-GFP puro was used as control.   
 
Titer of viral preparation 
To establish the titer of viral preparation, 10
5
 CD133+ blood derived stem cells were transduced with 
1, 5, 10 x 10
7
 ip/ml in a 96 wells plate (MOI of 5, 10, 20, respectively) immediately after cells 
isolation. Viral transduction was performed in 100 µl of DMEM supplemented with 10% FCS. 24 
hours post-transduction, fresh medium/well was added and cells were maintained at 37°C and 5% 
CO2. Each sample was evaluated in triplicate in three independent experiments. The transduction 
efficiency was evaluated after 6 days both by FACS -as % of GFP positive cells in 488 nm emission 
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wavelengths - and by green fluorescence cell count through Fiji Analyze Particles function (Image J). 
Cells transduced with higher MOI 20 have been also examined for impaired viability due to 
undesirable virus cytotoxic effects.  Trypan Blue Exclusion was performed every 5 days for 30 days 
on transduced and not transduced MDC1C CD133+ blood-derived stem cells, as previously described 
(27). Different lentiviral MOI effects on FKRP L276I
KI 
satellite cells were tested. On this purpose, 
10000 cells/well were seeded in a 48 wells plate and transduced with different lentivirus MOIs: 10, 
20, and 40. Not infected FKRP L276I
KI
 satellite cells were used as negative control. Infected and not 
infected satellite cell proliferation has been tested every 5 days by Trypan Blue Exclusion assay for 25 
days (28). We have also tested the effects of lentivirus vector carrying only the GFP expression 
cassette (RSV.GFP) to rule out the possibility of GFP cytotoxicity. Trypan Blue Exclusion Assay was 
performed on FKRP L276IKI satellite cells transduced with 10, 20, and 40 MOIs of the empty vector, 
as already described. Myogenic differentiation of infected (either with the vector carrying wild type 
FKRP or with empty vector) FKRP L276IKI satellite cells was induced in serum starvation culture 
conditions to detect unwanted MOI-related detrimental effects. Fusion Index (FI) was calculated after 
7 days as the number of nuclei in myotubes divided by the total number of nuclei. In order to visualize 
and count myotubes and nuclei, differentiated SCs were washed with PBS and fixed in ethanol 80% 
for 3 min. Cells were then stained with desmin antibody (1:50) (Abcam; Cambridge, UK) for 1 hour 
and counterstained with DAPI for nuclei visualization. Total cell nuclei and nuclei within myotubes 
were counted using the NIH ImageJ software. A muscle cell containing 3 or more nuclei was 
considered as a myotube, as previously defined (29).  
Western blot analysis and immunofluorescence staining of in vitro cell cultures 
MDC1C CD133+ blood derived stem cells and FKRP L276IKI satellite cells were harvested 7 days 
post infection and directly lysed using NP40 lysis buffer (20mM Tris-HCl (pH 7.8), 140mM NaCl, 
1mM EDTA, and 0.5% NP40, 1mM phenylmethylsulfonil fluoride) and complete protease inhibitor 
mixture (Roche; Basilea, Switzerland). Briefly, cell lysates were passed through a 30.5-gauge needle, 
incubated at 4°C for 15 min, and centrifuged at 12000g for 15 min at 4°C. Total protein concentration 
was determined according to Lowry’s method. 30 µg of samples were resolved on 10% 
polyacrylamide gel for wild type FKRP antibody or, alternatively, on 8% polyacrylamide gel for α-
DG detection and transferred to nitrocellulose membranes (Bio-Rad; Hercules, California, USA). 
FKRP-5643 (FKRP-STEM) antibody was gently supplied by Dr Qilong Lu and exploited for all the 
immunofluorescence and biochemical analyses described in this work (McColl Lockwood Laboratory 
for Muscular Dystrophy Research, Neuromuscular/ALS Center Carolinas Medical Center, Charlotte, 
North Carolina, USA). FKRP-STEM is a rabbit polyclonal antibody raised against the stem region 
(amino-acid residues 29–130) of the mouse FKRP, which is not able to detect a mutant isoform, but 
only the wild type FKRP. Therefore, WB bands and positive IF signal pertain to lentivirus mediated 
FKRP rescue. The filters were saturated in blocking solution (10 mM Tris (pH 7.4), 154 mM NaCl, 
1% BSA, 10% horse serum, and 0.075% Tween-20). The rabbit anti-FKRP antibody (1:600) was 
incubated overnight at 4°C. Mouse anti-α-DG (IIH6-C4-5, dilution 1:50) (Hybridoma Bank; Lowa, 
USA) was used to detect the level of -α-DG-glycosylation. Anti-β-actin (1:600) (Sigma Aldrich; St. 
Louis, USA) was detected as housekeeping protein. Detection was performed with horseradish 
peroxidase (HRP)-conjugated secondary antibodies (Dako; Glostrup, Denmark) (1 hour at room 
temperature), followed by enhanced chemiluminescence (ECL) development (GE Healthcare; Little 
Chalfont, UK). Pre-stained molecular weight markers (Bio-Rad Laboratories) were run on each gel. 
Bands were visualized by autoradiography using Amersham Hyperfilm™ (GE Healthcare; Little 
Chalfont, UK). Densitometric analysis was performed using ImageJ software 
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(http://rsbweb.nih.gov/ij/). For all the experiments not transduced MDC1C CD133+ blood derived 
stem cells and FKRP L276IKI satellite cells were used as controls. IF staining was performed on MOI 
20 infected FKRP L276IKI SCs to detect GFP and exogenous FKRP expression. Satellite cells were 
fixed with 4% paraformaldehyde for 5 minutes, pre-incubated blocking solution (1% BSA, 0,05% 
Tween, 5% FBS in PBS1X) for 30 minutes and stained for 2 hours with rabbit anti FKRP-STEM 
(dilution 1:50) and mouse anti-GFP (dilution 1:500) (Abcam; Cambridge, UK) antibodies. 
Monoclonal anti-rabbit 594 and monoclonal anti-mouse 488 (Molecular Probe, Thermo Fisher 
Scientific; Waltham, Massachusetts, USA) were added at a dilution of 1:100 in PBS for 1 hour. 
Nuclei were stained with DAPI (Sigma-Aldrich; St. Louis, USA). Images were captured with Leica 
TCS SP2 confocal microscope (Leica, Germany). 
In vitro exosome carrying FKRP release from transduced MDC1C CD133+blood derived stem 
cells and FKRP L276I
KI
 satellite cells. 
Exosome isolation and protein quantification from cell supernatants 
Cell culture media (CM) were harvested from engineered CD133+ blood-derived stem cells and 
FKRP L276I
KI
 satellite cells after 24h in serum-free conditions and immediately centrifuged at 2000 g 
for 30 minutes to remove cell debris. 15 ml of supernatants from each condition were then 
concentrated by Amicon Ultra 10k MWCO filters (Merck Millipore; Darmstadt, Germany) to a final 
volume of 500 µl.  Subsequently, size exclusion chromatography (SEC) was performed, exploiting the 
qEV Size Exclusion Columns (30). Briefly, the 500 µl of concentrated supernatants were loaded on 
columns and elution was performed using PBS 1X as elution buffer. 0.5 mL fractions of the sample 
were collected. The protein concentration of each fraction was measured by microBCA Protein Assay 
Kit (Thermo Fisher Scientific; Waltham, Massachusetts, USA). 
Exosome characterization   
To characterize exosomes by transmission electron microscopy (TEM) analysis, the pellet was 
resuspended in PBS 1X and 5µl were directly loaded onto formvarcarbon-coated grids. (31, 32). The 
evaluation of vesicle absolute size distribution was performed using NanoSight LM10 (Malvern, UK). 
The NTA measurement conditions were settled: temperature 23.75±0.5°C; viscosity 0.91±0.03 cP, 
frames per second 25, measurement time 60s. N=3 recordings were performed for each sample (31, 
32). To perform FACS analysis, 2 µg of exosomes were incubated for 20 minutes at 4°C with CD63-
PE-vio770 (Miltenyi Biotech; Bergisch Gladbach, Germany), and CD81-PE (Beckman Coulter; Brea, 
California, USA) antibodies. After that, the mix was added with 10 µl of magnetic CD63-coniugated 
beads (Thermo Fisher Scientific;Waltham, Massachusetts, USA) and incubated overnight at 4 °C 
under gentle rotation. After staining, exosome suspensions were washed in PBS containing 1% heat 
inactivated exosome-depleted foetal calf serum and 0.1% sodium azide. The cytometric analysis was 
performed on a FACS Cytomic FC 500. Each analysis included at least 100000 events. The analysis 
was conducted using CXP 2.1 software. For WB analysis on exosomes, 5 µg of fraction 9-enriched 
exosomes were mixed with Laemmli sample buffer (62.5 mM Tris-HCl pH 6.8; 2% SDS; 5% 2-
mercaptoethanol, glycerol 10%, Bromophenol Blue 0.004%), boiled at 65 °C for 10 minutes and 
resolved on 10% polyacrylamide gel, transferred to supported nitrocellulose membranes, and the 
filters were saturated in blocking solution (10 mM Tris pH 7.4, 154 mM NaCl, 1% BSA, 10% horse 
serum, and 0.075% Tween-20). Anti-TSG 101 (1:200)(Abcam; Cambridge, UK), anti-Ago2 (1:200) 
(Proteintech, Europe; Manchester, UK), and anti FKRP-STEM (1:600) antibodies were incubated 
overnight at 4°C in the blocking solution or, alternatively, exploiting the Signal-boost 
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Immunoreaction Enhancer Kit (Calbiochem; Inalco, Italy), when the enhancement of the signal was 
required. Detection was performed with horseradish peroxidase (HRP)-conjugated secondary 
antibodies, followed by enhanced chemiluminescence (ECL) development. Prestained molecular 
weight markers were run on each gel. Bands were visualized by autoradiography using Amersham 
Hyperfilm™. Images of bands were obtained using the CanoScan LiDE60 Scanner and the Canon 
ScanGear Software. Densitometric analysis was performed using ImageJ software 
(http://rsbweb.nih.gov/ij/). 
In vitro modelling of dynamic FKRP carrying- exosome trafficking 
In order to mimic the FKRP trafficking within exosomes, a miniaturized, microfluidic bioreactor was 
employed and set up as described elsewhere with minor modifications (33). The dynamic system is 
optically transparent and composed of three independent chambers, each hosting one independent 
polystyrene scaffold for cell culture (dimensions 6 × 3 × 0.4 mm, 3D Biotek; Hillsborough, NJ, USA). 
These scaffolds are composed of four layers of fibers (100 µm in diameter, with a pore size of 300 
µm) shifted of 150 µm with respect to the adjacent (Fig 4A).  
Three independent microfluidic channels, directly machined in the bioreactor body, perfuse the 
chambers.  Scaffolds were pre-conditioned in sterile conditions with cell culture medium, as already 
described (34). The day after 10
6
 FKRP L276I
KI 
satellite cells transduced with LV-MOI 20 were 
labelled with PKH26 red marker, according to manufacturers’ protocol, in order to release PKH26+ 
exosomes (35) and plated in 400µl into one scaffold. Likewise, another scaffold was seeded with not 
labelled 10
5
 FKRP L276I
KI 
satellite cells. The constructs were then maintained at 37 °C overnight to 
let cells adhere, and then they were moved into two independent bioreactor chambers, which were 
sealed by magnetic covers. DMEM 10% FCS was pumped with an unidirectional flow rate of 5 
µl/min into the first chamber hosting transduced FKRP L276IKI satellite cells by a multi-channel 
programmable syringe pump (PHDULTRA, Harvard Apparatus, Holliston, MA, USA) in a gas 
permeable tubing system (0.03′′ ID × 0.065′′ OD, Silastic Tubing, Cole-Parmer, Vernon Hills, IL, 
USA). The outward medium, enriched with exosomes released from PKH26+ infected FKRP L276I
KI 
satellite cells, entered the second chamber containing FKRP L276I
KI 
satellite cells, and thereafter it 
was collected in a reservoir. The experiment was carried out for 8 hours, and then the scaffolds were 
transferred into a 48-wells plates and treated for IF staining of exosome mediated-FKRP expression. 
Scaffolds containing FKRP L276I
KI 
satellite cells were fixed with 4% paraformaldehyde for 30 
minutes, pre-incubated with blocking solution (1% BSA, 0,05% Tween, 5% FBS in PBS1X) for 1 
hour and stained overnight at 4°C with rabbit anti FKRP-STEM antibody in blocking solution (diluted 
1: 50). Monoclonal anti-rabbit 488 (Molecular Probe; Thermo Fisher Scientific; Waltham, 
Massachusetts, USA) was added at a dilution of 1:100 in PBS for 1 hour. Nuclei were stained with 
DAPI (Sigma-Aldrich; St. Louis, USA) and images were captured with Leica TCS SP2 confocal 
microscope.  
In vivo transplantation of LV-FKRP L276I
KI
 satellite cells into FKRP L276I
KI
 mouse models  
For in vivo transplantation, 12 months old FKRP L276I
KI
 mice were anesthetized with 2 % avertin 
(0.015 mL/kg) and injected in the tibialis anterior (TA) with 35x10
3
 (N= 4), 75x10
3
 (N=5), and 
100x103 (N=4) FKRP L276IKI satellite cells transduced with MOI 20 in 100 µl of PBS, using a 33G 
Hamilton syringe (Hamilton; Reno, Nevada, USA). N=6 mice were not injected and used as control. 
Two weeks later, the mice were sacrificed by cervical dislocation.  
Immunofluorescence and WB analyses 
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Both TA muscles were removed from injected and not-injected FKRP L276IKI mice and frozen in 
liquid nitrogen–cooled isopentane for IF staining, or directly lysed in specific buffer for biochemical 
analysis.  For the evaluation of systemic distribution of FKRP protein in distal compartments, hearts 
(HT) were also removed and processed for WB analyses. 
For IF, serial TA muscle sections of 12 µm thickness were cut by cryostat (Leica CM1850). Staining 
of sections was performed for FKRP with rabbit anti FKRP-STEM antibody (diluted 1: 50), and 
mouse anti-GFP (dilution 1:500) (Abcam; Cambridge, UK). Tissue sections were also stained with 
mouse anti-Dystroglycan IIH6-C4-5 (1:50) (Hybridoma Bank; Lowa, USA), directed against glycan 
epitopes of α-DG. Monoclonal anti-rabbit 594, monoclonal anti-mouse 594 and monoclonal anti-
mouse 488 (Molecular Probe; Thermo Fisher Scientific; Waltham, Massachusetts, USA) were added 
at a dilution of 1:100 for 1 hour. Nuclei were stained with DAPI (Sigma-Aldrich; St. Louis, USA) and 
images were captured with Leica TCS SP2 confocal microscope. For WB analyses, TAs and HTs 
from all the FKRP L276IKI mice, injected and not injected, were homogenized in NP40 lysis buffer 
using a POTTER S Homogenizer (B. Braun Biotech International-Sartorius group; Melsungen, 
Germany). Sample were then incubated at 4 °C for 15 min and finally centrifuged at 12000g for 15 
min at 4 °C. Total protein concentration was determined according to Lowry’s method. 30 µg of each 
sample was loaded on 10 % polyacrylamide gel for wild type FKRP detection (FKRP-STEM 
antibody, dilution 1:600), and on 8% polyacrylamide gel for α-DG detection (IIH6-C4-5, dilution 
1:50) and transferred to nitrocellulose membranes (Bio-Rad; Hercules, California, USA). Anti-α-actin 
(1:600)(Sigma Aldrich; St. Louis, USA) was detected as housekeeping protein. For WB analyses TAs 
and HTs from C57Bl mice were considered as positive controls. 
Histopathology of FKRP L276I
KI
 muscle tissues 
Frozen TA muscles from injected and not-injected FKRP L276IKI mice and cut by cryostat (Leica 
CM1850) in 12 µm thickness muscle sections for Haematoxylin and Eosin (H&E)(Sigma Aldrich; St. 
Louis, USA). TA from C57Bl mouse was used as control.  
Isolation of circulating plasma exosomes carrying FKRP protein from injected FKRP L276IKI mice  
Immediately before sacrifice, 300 µl of blood were collected into EDTA-coated tubes from the 
submandibular vein of the 35x10
3
, 75x10
3
, and 100x10
3
 engineered satellite cells injected FKRP 
L276I
KI
 mice. The whole blood was then centrifuged at 1200g for 10 minutes at 4°C to separate 
plasma. Plasma was transferred to a 1.5 ml tubes and stored at - 80 °C until use. Exosomes were 
isolated from the plasma using SEC device (qEV IZON Science; Scheafer, South East Europe) after 
diluting samples 1:2 with filtered PBS1X. According to the manufacturer’s instructions, the first six 
eluted fractions are considered the “void volume” and discharged, while exosomes were 
predominantly found in fractions 7, 8, and 9. The last elution volumes, considered depleted from 
exosomes, were store and analysed to determine the presence of free FKRP circulation not mediated 
by exosomes. The plasma exosome expression of wild type FKRP was evaluated throughout western 
blot analyses using anti FKRP-STEM antibody, as previously described for supernatant exosomes 
derived from MDC1C CD133+ blood-derived cells and FKRP L276IKI SCs.  For FKRP detection of 
mice plasma, 5µl of samples were directly mixed with Laemmli buffer and processed as already 
described. 
Functional measurements 
Treadmill and Rotarod tests were performed on all the mice injected with 35 (n=4), 75 (n=5), and 100 
(n=4) x103 engineered FKRP L276IKI satellite cells for measuring the mice endurance. N=6 FKRP 
17 
L276IKI not injected mice and n=5 age-matched C57Bl mice were used as controls. Four different 
time points were evaluated: 7 days before cell injection, the transplantation day (T0), and 7 and 14 
days after (T7 and T14), after that the animals were sacrificed. Treadmill was conducted as a simple 
motor exercise as reported by (10). Briefly, animals were placed on a motorized treadmill (Harvard 
Apparatus; Holliston, Massachusetts, USA) to run with an upward angle of 15° at a rate of 
15m/minute. In order to account for the high inter-individual variability, running meter outcomes 
from treated and untreated groups at T14 were also normalized to pre-exercise (7 days before the cell 
treatment) results for each FKRPL276I
KI
 mouse, considered as “baseline level”. The data for each 
group are now presented as percentage of averaged changes in running meters, calculated as 
[(Activity at T14/Activity 7days before the injections) × 100] – 100.The measurement was stopped 
when the mice spent 5 seconds blocked on the shock grid. Rotarod is a relatively complex motor 
training procedure, testing balance and coordination aspects of motor performance. Mice were placed 
on the rod that accelerated from 5 to 45 rotations/ minute within 15 seconds. When a mouse ran for 
500 seconds without falling from the rod, the test session was ended. Mice that fell off within 500 
seconds were given a maximum of two more tries. The longest running time was used for the 
analysis. 
Statistical analysis 
Statistical analysis. Prism 5.0 (Graphpad) was used for analysis. Statistical comparisons were based 
on Student's t-test or analysis of variance (ANOVA) with Tukey post-hoc test for pairwise 
comparisons. A confidence level of 95% was considered significant. P-values < 0.05 were considered 
significant. 
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FIGURE LEGENDS 
Figure 1. 
Characterization of CD133+ blood-derived stem cells isolated from a MDC1C patient. Cells 
morphology was evaluated by bright field microscopy (Leica LMD6000B) immediately after cells 
isolation (A) and after 14 days in proliferation medium (B). Images were captured at 20X 
magnification.  FACS immunophenotyping of isolated blood-derived CD133+ stem cells. Each study 
included at least 15,000–30,000 events. The scatter plot is reported (C). The median purity of 
positively selected CD133+ stem cells after magnetic cell sorting was about 92,3% (C’); 98% of 
CD133+ cells co-expressed CD45 (C’’) and 90,1 % of the isolated cell population was also CD34+ 
(C’’’). FACS immunophenotyping of CD133+ blood-derived stem cells infected with the lentiviral 
vector (pLenti-CAG (hFKRP)-Rsv (GFP-Puro)). The percentage of GFP+ cells was 48% (MOI 5) 
20 
(D), 74.8% (MOI 10) (D’) and 95.2% (MOI 20) (D’’), respectively. Representative histogram of 
CD133+ stem cells transduction efficiency at MOI 5, 10 and 20 (D’’’). Values are expressed as means 
± SD. MOI 20 infected and not infected MDC1C CD133+ blood-derived stem cells proliferation 
curve. Proliferation was evaluated in triplicate at different time-points (5-days intervals for 30 days) 
by counting cells with Trypan Blue Exclusion Assay (E). Values are expressed as means ± SD. 
Immunoblotting analysis confirmed FKRP protein expression (60 KDa) in MDC1C CD133+ blood-
derived stem cells infected with the LV-hFKRP lentiviral vector at MOI 20 (MOI 20 INF CD133+ 
MDC1C, lane 3). Not infected MDC1C CD133+ cells (CD133+ MDC1C, lane 2) and healthy 
CD133+ (CD133+ CTR+, lane 1) were respectively loaded as positive and negative controls. β-actin 
was used as house-keeping protein (43 KDa) (F).  
Figure 2.  
Characterization of FKRP L276I
KI
 satellite cells. FACS immunophenotyping of freshly isolated 
FKRP L276I
KI
 satellite cells. Each study included at least 15,000–30,000 events. 97,6% cells were 
PAX7+ (A), 80,3% of PAX7+ cells co-expressed CD29 marker (A’). Cells morphology was 
evaluated by bright field microscopy at different time-points: immediately after cells seeding (T0) 
(B), after 7 days (T7) (C) and 14 days (T14) (D) in myogenic differentiation medium (serum 
starvation condition). Immunofluorescent analysis was performed to evaluate specific myogenic 
satellite markers expression. At T0, satellite clones were positive for α-desmin (in green) and Pax7 (in 
red) (E). At T7 cells lost the expression of the early myogenic marker Pax7, and maintained the 
expression of α-desmin; α -desmin staining highlighted the presence of a few myotubes (F). At T14, 
cells were still positive for α-desmin and were finally fused to form myotubes (G). Images were 
captured at 20X magnification. LV-FKRP infected and not infected satellite cells proliferation curve 
(H) and LV-EMPTY infected and not infected satellite cells proliferation curve (I). SCs proliferation 
was evaluated every 5 days for 25 days by counting cells with Trypan Blue Exclusion Assay. Values 
are expressed as means ± SD. Evaluation of LV-FKRP infected (MOI 10, 20 and 40) and not infected 
(NOT INF) satellite cells fusion index, representing the % of myotubes nuclei/ number of total nuclei, 
after 7 days in serum starvation (L). Values are expressed as means ± SD. Immunoblotting analysis 
confirmed α-DG protein glycosylation (smeared band 150 KDa) and FKRP protein expression (60 
KDa) in infected satellite cells. α-DG signal was slightly increased between not-injected cells (NOT-
INF, lane 1) and LV-FKRP injected cells, but showed no differences between MOI 10, 20 and 40 
(MOI 10, lane 2, MOI 20, lane 3, MOI 40, lane 4). FKRP positive signal increased between MOI 10 
and 20 but reached a plateau with MOI 40, not infected FKRP L276IKI satellite cell lysate was used as 
negative control. β-actin (43 KDa) was used as house-keeping protein (M). Immunofluorescent 
analysis of MOI 20 infected satellite cells, showing both cytoplasmic and perinuclear FKRP (in red) 
and cytoplasmic GFP (in green) expression. Nuclei were stained with Dapi (in blu). Images were 
taken with a confocal microscope (Leica SP2) at 63X magnification (N). 
Figure 3. 
Exosomes characterization. Nanosight Tracking Analysis (NTA) of exosomes derived from MOI 20 
infected MDC1C CD133+ blood-derived cells (A) and FKRP L276I
KI
 satellite cells (B). Plots 
represent the average value of three recordings performed for each sample. Size and particle 
distribution (concentration) are reported. FACS immunophenotyping of MOI 20 transduced MDC1C 
CD133+ stem cells- (C) and MOI 20 transduced FKRP L276IKI satellite cells- released exosomes (D).  
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Each study included at least 100,000 events. 92,2% of CD133+-derived exosomes were CD63+ and 
82,5% were CD81+; 88% of SCs-derived exosomes were CD63+ and 89% CD81+. Magnified view 
of Transmission Electron Microscopy (TEM) micrograph of exosomes released from transduced MOI 
20 MDC1C CD133+ blood-derived stem cells (mean value 92,7 nm ± 39,5 nm SD) (E) and FKRP 
L276I
KI 
satellite cells (mean value 109 nm ± 46,3 nm SD)(F). Exosome diameters were measured 
using NIH ImageJ software. Scale bar, 200 nm. Western blot analysis of exosomal TSG-101, AGO2 
and FKRP proteins extracted from MOI 20 transduced MDC1C CD133+ stem cells- (MOI 20 INF 
MDC1C CD133+ EXOs, lane 2) and MOI 20 FKRP L276I
KI 
satellite cells- (MOI 20 INF L276I
KI
 
FKRP EXOs, lane 4) derived exosomes. MOI 20 infected CD133+ blood-derived cell lysate (MOI 20 
INF MDC1C CD133+, lane 1) and MOI 20 infected satellite cells lysate (MOI 20 INF L276I
KI
 FKRP, 
lane 3) were loaded as positive controls. 
 
Figure 4. 
Immunoblotting analysis of 12 months-old FKRP L276IKI mice injected muscles. N=4 FKRP L276IKI 
mice were transplanted with 35x103 (lanes #1, #2, #3, #4) (A, D), N=5 with 75x103 (lanes #5, #6, #7, 
#8, #9) (B, D) and N=4 with 100x103 (lanes #10, #11, #12, #13) MOI 20 transduced FKRP L276IKI 
SCs cells (C, E). Both injected (+ lanes) and not-injected (- lanes) TAs were analysed for the 
expression of FKRP protein. WB analysis of α-dystroglycan (α-DG) glycosylation was evaluated in 
the TAs of injected muscles (lanes +) (D, E). N=6 not injected FKRP L276I
KI 
TAs (lanes NI) were 
analysed as controls (A). C57BL TA was loaded as positive control (lane CTR+) (C) 
Figure 5. 
Immunofluorescent staining of not injected FKRP L276I
KI
 (FKRP L276I
KI
 NI) TAs and FKRP 
L276I
KI
 TAs injected with 35x10
3
 , 75x10
3
 , 100x10
3
 engineered satellite cells (FKRP L276I
KI
 35K, 
75K, 100K). Sections were stained for the expression of exogenous FKRP (in red) (A, B, C, D). 
Fig.5C and D inserts showed perinuclear exogenous FKRP staining. GFP staining was performed to 
evidence GFP protein expression and localization (in green) (A’, B’, C’, D’). Merge of FKRP (in red) 
and GFP (in green) is also reported (A’’, B’’, C’’, D’’). Muscle sections were also analysed for the 
expression of α-DG glycosylation using IIH6C4-s antibody (in red) (A’’’, B’’’, C’’’, D’’’). Nuclei 
were stained with Dapi. Images were taken at 40X magnification. Scale bar=75 µm. 
Figure 6. 
Western blot analysis of plasma- derived exosomes. Exosomes were isolated from the plasma of 12 
months- old FKRP L276I
KI
 mice injected with 35x10
3 
(lane 35K), 75x10
3 
(lane 75K), 100x10
3 
(lane 
100K) FKRP L276IKI SCs transduced cells. Plasma was collected immediately before the animal 
sacrifice. Exosomes were evaluated for the expression of FKRP protein and TSG-101 exosomal 
marker expression. Plasma-derived exosomes isolated from not injected mice were exploited as 
control (lane NI) (A). TEM image representative of plasma exosomes morphology (mean size 90 nm 
± 36,6 nm SD). Scale bar: 200nm (B). NTA graph representative of plasma-derived exosomes 
concentration and dimensions (C). Immunoblotting analysis of FKRP L276IKI engineered SCs-
injected mice hearts. FKRP expression (D) and α-DG glycosylation (E) were evaluated in N=4 mice 
transplanted with 35x10
3
 (lanes #1, #2, #3, #4), N=5 with 75x10
3
 (lanes #5, #6, #7, #8, #9), and N=4 
with 100x10
3
 (lanes #10, #11, #12, #13) engineered SCs. Not injected FKRP L276I
KI 
heart muscle 
was used as negative control (lane NI). C57BL heart muscle was exploited as positive control (lane 
CTR+) (D, E). 
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Figure 7. 
Schematic representation of the bioreactor. The bioreactor is composed of three scaffolds (6x3 mm, 
400µm thickness, 0,6 µm fiber pore size), connected by microfluidic channels. PKH26+ FKRP 
L276I
KI
 satellite cells were seeded on the first scaffold and secreted PKH26+ exosomes, able to reach 
not-infected SCs seeded on the second scaffold, running through a microfluidic channel connecting 
the two chambers (A). IF analysis of infected FKRP L276I
KI
 SCs; GFP signal was detected in the cell 
cytoplasm (B).  PKH26- labelled FKRP L276I
KI
 SCs cells (C). PKH26- exosomes secreted by 
PKH26- labelled FKRP L276I
KI
 SCs cells (D). Images were taken at 100X magnification. 
Immunofluorescent analysis of not-infected SCs seeded on the second scaffold. PKH26+ exosomes- 
(in red) targeted SCs recovered the expression of wild-type FKRP (in green). Nuclei were stained 
with Dapi (E, F).  
Figure 8. 
Muscle functional tests. Mice endurance was evaluated by treadmill test (A, B) and Rotarod test (C). 
C57BL mice (N=5), not injected (N=6), 35x103 (N=4), 75x103 (N=5), and 100x103 (N=4) MOI 20 
transduced FKRP L276IKI  SCs- injected mice have been tested at different time points: 7 days before 
the cell injection (7 days pre-INJ), the day of cells transplantation (T0), and over the course of the 
time at 7 and 14 days (T7, T14), before the animal sacrifice. Values are means ± SD. P-value <0.05 
was considered statistically significant. 
ABBREVIATIONS 
LV-FKRP Cells transduced with lentiviral vector expressing the wild type isoform of human FKRP 
gene 
CMD Congenital Muscular Dystrophies 
α-DG  α-Dystroglycan 
ECM  Extracellular Matrix 
POMT1 Protein-O-mannosyl transferase 1 
POMT2 Protein-O-mannosyl transferase 2 
FKRP Fukutin-Related Protein 
MDC1C Congenital Muscular Dystrophy type 1 
LGMD2I Limb Girdle Muscular Dystrophy type 2I 
Rbo5P Ribitol 5-phosphate 
CDP-ribitol cytidine 5′-diphosphate 
ER Endoplasmatic Reticulum 
GFP Green Fluorescent Protein 
SEC Size-Exclusion Chromatography 
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TEM Transmission Electron Microscopy 
NTA Nanosight Tracking Analysis 
SCs Satellite cells 
TA Tibialis Anterior 
HT Heart 
FCMD Fukuyama type congenital muscular dystrophy 
MEB Muscle-eye-brain disease 
WWS Walker-Warburg syndrome 
POMGnT O-mannose beta-1,2-N-acetylglucosaminyltransferase 1 
ISPD isoprenoid synthase domain-containing protein 
β2GALNT2 beta-2-Polypeptide N-Acetylgalactosaminyltransferase 
SGK196 protein-O-mannose kinase 
β3GNT1 Beta-1,4-Glucuronyltransferase 
TMEM5 transmembrane protein 5 
DOLK dolichol kinase 
GMPPB GDP-Mannose Pyrophosphorylase B 
DMP1 Dentin Matrix Acidic Phosphoprotein 1 
DMP2 Dentin Matrix Acidic Phosphoprotein 2 
DMP3 Dentin Matrix Acidic Phosphoprotein 3 
LARGE glycosyltransferase-like-protein 
AVV9 Adenoviral-associated vector 
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Characterization of CD133+ blood-derived stem cells isolated from a MDC1C patient. Cells morphology was 
evaluated by bright field microscopy (Leica LMD6000B) immediately after cells isolation (A) and after 14 
days in proliferation medium (B). Images were captured at 20X magnification.  FACS immunophenotyping of 
isolated blood-derived CD133+ stem cells. Each study included at least 15,000–30,000 events. The scatter 
plot is reported (C). The median purity of positively selected CD133+ stem cells after magnetic cell sorting 
was about 92,3% (C’); 98% of CD133+ cells co-expressed CD45 (C’’) and 90,1 % of the isolated cell 
population was also CD34+ (C’’’). FACS immunophenotyping of CD133+ blood-derived stem cells infected 
with the lentiviral vector (pLenti-CAG (hFKRP)-Rsv (GFP-Puro)). The percentage of GFP+ cells was 48% 
(MOI 5) (D), 74.8% (MOI 10) (D’) and 95.2% (MOI 20) (D’’), respectively. Representative histogram of 
CD133+ stem cells transduction efficiency at MOI 5, 10 and 20 (D’’’). Values are expressed as means ± SD. 
MOI 20 infected and not infected MDC1C CD133+ blood-derived stem cells proliferation curve. Proliferation 
was evaluated in triplicate at different time-points (5-days intervals for 30 days) by counting cells with 
Trypan Blue Exclusion Assay (E). Values are expressed as means ± SD. Immunoblotting analysis confirmed 
FKRP protein expression (60 KDa) in MDC1C CD133+ blood-derived stem cells infected with the LV-hFKRP 
lentiviral vector at MOI 20 (MOI 20 INF CD133+ MDC1C, lane 3). Not infected MDC1C CD133+ cells 
(CD133+ MDC1C, lane 2) and healthy CD133+ (CD133+ CTR+, lane 1) were respectively loaded as positive 
and negative controls. β-actin was used as house-keeping protein (43 KDa) (F).  
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Characterization of FKRP L276IKI satellite cells. FACS immunophenotyping of freshly isolated FKRP L276IKI 
satellite cells. Each study included at least 15,000–30,000 events. 97,6% cells were PAX7+ (A), 80,3% of 
PAX7+ cells co-expressed CD29 marker (A’). Cells morphology was evaluated by bright field microscopy at 
different time-points: immediately after cells seeding (T0) (B), after 7 days (T7) (C) and 14 days (T14) (D) 
in myogenic differentiation medium (serum starvation condition). Immunofluorescent analysis was 
performed to evaluate specific myogenic satellite markers expression. At T0, satellite clones were positive 
for α-desmin (in green) and Pax7 (in red) (E). At T7 cells lost the expression of the early myogenic marker 
Pax7, and maintained the expression of α-desmin; α -desmin staining highlighted the presence of a few 
myotubes (F). At T14, cells were still positive for α-desmin and were finally fused to form myotubes (G). 
Images were captured at 20X magnification. LV-FKRP infected and not infected satellite cells proliferation 
curve (H) and LV-EMPTY infected and not infected satellite cells proliferation curve (I). SCs proliferation was 
evaluated every 5 days for 25 days by counting cells with Trypan Blue Exclusion Assay. Values are 
expressed as means ± SD. Evaluation of LV-FKRP infected (MOI 10, 20 and 40) and not infected (NOT INF) 
satellite cells fusion index, representing the % of myotubes nuclei/ number of total nuclei, after 7 days in 
serum starvation (L). Values are expressed as means ± SD. Immunoblotting analysis confirmed α-DG 
protein glycosylation (smeared band 150 KDa) and FKRP protein expression (60 KDa) in infected satellite 
cells. α-DG signal was slightly increased between not-injected cells (NOT-INF, lane 1) and LV-FKRP injected 
cells, but showed no differences between MOI 10, 20 and 40 (MOI 10, lane 2, MOI 20, lane 3, MOI 40, lane 
4). FKRP positive signal increased between MOI 10 and 20 but reached a plateau with MOI 40, not infected 
FKRP L276IKI satellite cell lysate was used as negative control. β-actin (43 KDa) was used as house-keeping 
protein (M). Immunofluorescent analysis of MOI 20 infected satellite cells, showing both cytoplasmic and 
perinuclear FKRP (in red) and cytoplasmic GFP (in green) expression. Nuclei were stained with Dapi (in blu). 
Images were taken with a confocal microscope (Leica SP2) at 63X magnification (N).  
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Exosomes characterization. Nanosight Tracking Analysis (NTA) of exosomes derived from MOI 20 infected 
MDC1C CD133+ blood-derived cells (A) and FKRP L276IKI satellite cells (B). Plots represent the average 
value of three recordings performed for each sample. Size and particle distribution (concentration) are 
reported. FACS immunophenotyping of MOI 20 transduced MDC1C CD133+ stem cells- (C) and MOI 20 
transduced FKRP L276IKI satellite cells- released exosomes (D).  Each study included at least 100,000 
events. 92,2% of CD133+-derived exosomes were CD63+ and 82,5% were CD81+; 88% of SCs-derived 
exosomes were CD63+ and 89% CD81+. Magnified view of Transmission Electron Microscopy (TEM) 
micrograph of exosomes released from transduced MOI 20 MDC1C CD133+ blood-derived stem cells (mean 
value 92,7 nm ± 39,5 nm SD) (E) and FKRP L276IKI satellite cells (mean value 109 nm ± 46,3 nm SD)(F). 
Exosome diameters were measured using NIH ImageJ software. Scale bar, 200 nm. Western blot analysis of 
exosomal TSG-101, AGO2 and FKRP proteins extracted from MOI 20 transduced MDC1C CD133+ stem cells- 
(MOI 20 INF MDC1C CD133+ EXOs, lane 2) and MOI 20 FKRP L276IKI satellite cells- (MOI 20 INF L276IKI 
FKRP EXOs, lane 4) derived exosomes. MOI 20 infected CD133+ blood-derived cell lysate (MOI 20 INF 
MDC1C CD133+, lane 1) and MOI 20 infected satellite cells lysate (MOI 20 INF L276IKI FKRP, lane 3) were 
loaded as positive controls.  
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Immunoblotting analysis of 12 months-old FKRP L276IKI mice injected muscles. N=4 FKRP L276IKI mice 
were transplanted with 35x103 (lanes #1, #2, #3, #4) (A, D), N=5 with 75x103 (lanes #5, #6, #7, #8, #9) 
(B, D) and N=4 with 100x103 (lanes #10, #11, #12, #13) MOI 20 transduced FKRP L276IKI SCs cells (C, 
E). Both injected (+ lanes) and not-injected (- lanes) TAs were analysed for the expression of FKRP protein. 
WB analysis of α-dystroglycan (α-DG) glycosylation was evaluated in the TAs of injected muscles (lanes +) 
(D, E). N=6 not injected FKRP L276IKI TAs (lanes NI) were analysed as controls (A). C57BL TA was loaded 
as positive control (lane CTR+) (C)  
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Figure 5.  
Immunofluorescent staining of not injected FKRP L276IKI (FKRP L276IKI NI) TAs and FKRP L276IKI TAs 
injected with 35x103 , 75x103 , 100x103 engineered satellite cells (FKRP L276IKI 35K, 75K, 100K). Sections 
were stained for the expression of exogenous FKRP (in red) (A, B, C, D). Fig.5C and D inserts showed 
perinuclear exogenous FKRP staining. GFP staining was performed to evidence GFP protein expression and 
localization (in green) (A’, B’, C’, D’). Merge of FKRP (in red) and GFP (in green) is also reported (A’’, B’’, C’’, 
D’’). Muscle sections were also analysed for the expression of α-DG glycosylation using IIH6C4-s antibody 
(in red) (A’’’, B’’’, C’’’, D’’’). Nuclei were stained with Dapi. Images were taken at 40X magnification. Scale 
bar=75 µm.  
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Figure 6.  
Western blot analysis of plasma- derived exosomes. Exosomes were isolated from the plasma of 12 months- 
old FKRP L276IKI mice injected with 35x103 (lane 35K), 75x103 (lane 75K), 100x103 (lane 100K) FKRP 
L276IKI SCs transduced cells. Plasma was collected immediately before the animal sacrifice. Exosomes were 
evaluated for the expression of FKRP protein and TSG-101 exosomal marker expression. Plasma-derived 
exosomes isolated from not injected mice were exploited as control (lane NI) (A). TEM image representative 
of plasma exosomes morphology (mean size 90 nm ± 36,6 nm SD). Scale bar: 200nm (B). NTA graph 
representative of plasma-derived exosomes concentration and dimensions (C). Immunoblotting analysis of 
FKRP L276IKI engineered SCs-injected mice hearts. FKRP expression (D) and α-DG glycosylation (E) were 
evaluated in N=4 mice transplanted with 35x103 (lanes #1, #2, #3, #4), N=5 with 75x103 (lanes #5, #6, 
#7, #8, #9), and N=4 with 100x103 (lanes #10, #11, #12, #13) engineered SCs. Not injected FKRP 
L276IKI heart muscle was used as negative control (lane NI). C57BL heart muscle was exploited as positive 
control (lane CTR+) (D, E).  
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Figure 7.  
Schematic representation of the bioreactor. The bioreactor is composed of three scaffolds (6x3 mm, 400 µm 
thickness, 0,6 µm fiber pore size), connected by microfluidic channels. PKH26+ FKRP L276IKI satellite cells 
were seeded on the first scaffold and secreted PKH26+ exosomes, able to reach not-infected SCs seeded on 
the second scaffold, running through a microfluidic channel connecting the two chambers (A). IF analysis of 
infected FKRP L276IKI SCs; GFP signal was detected in the cell cytoplasm (B).  PKH26- labelled FKRP 
L276IKI SCs cells (C). PKH26- exosomes secreted by PKH26- labelled FKRP L276IKI SCs cells (D). Images 
were taken at 100X magnification. Immunofluorescent analysis of not-infected SCs seeded on the second 
scaffold. PKH26+ exosomes- (in red) targeted SCs recovered the expression of wild-type FKRP (in green). 
Nuclei were stained with Dapi (E, F).  
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Figure 8.  
Muscle functional tests. Mice endurance was evaluated by treadmill test (A, B) and Rotarod test (C). C57BL 
mice (N=5), not injected (N=6), 35x103 (N=4), 75x103 (N=5), and 100x103 (N=4) MOI 20 transduced FKRP 
L276IKI  SCs- injected mice have been tested at different time points: 7 days before the cell injection (7 
days pre-INJ), the day of cells transplantation (T0), and over the course of the time at 7 and 14 days (T7, 
T14), before the animal sacrifice. Values are means ± SD. P-value <0.05 was considered statistically 
significant.  
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